Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Alphatec Holdings Inc (ATEC) Com Stk USD0.0001

Sell:$13.88 Buy:$13.89 Change: $0.41 (2.87%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.41 (2.87%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.41 (2.87%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alphatec Holdings, Inc. is a medical technology company. The Company, through its subsidiary, Alphatec Spine, Inc., and its subsidiaries, designs, develops, manufactures, and markets products for the surgical treatment of spine disorders. The Company offers Organic Innovation Machine, which is focused on developing technology to treat spine’s various pathologies. The Company provides multiple lordosis and footprint options to accommodate varying surgical requirements across all interbody fusion procedures including ACDF, ALIF, LIF, PLIF, and TLIF. The Company’s subsidiaries include Alphatec Spine, Inc., Alphatec Holdings International C.V., Scient'x S.A.S., and Surgiview S.A.S., HealthpointCapital, LLC, HealthpointCapital Partners, L.P., HealthpointCapital Partners II, L.P., John H. Foster and Mortimer Berkowitz III, and Orthotec, LLC and Patrick Bertranou.

Contact details

5818 El Camino Real
United States
+1 (760) 4319286

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.43 billion
Shares in issue:
100.12 million
Health Care Equipment
United States
US dollar

Key personnel

  • Patrick Miles
    Chairman of the Board, President, Chief Executive Officer
  • J. Todd Koning
    Chief Financial Officer, Executive Vice President
  • Craig Hunsaker
    Executive Vice President - People and Culture, General Counsel
  • David Sponsel
    Executive Vice President - Sales
  • Brian Snider
    Executive Vice President - Marketing
  • Eric Dasso
    Executive Vice President - Adjunctive Technologies
  • Kelli Howell
    Executive Vice President - Clinical Strategies
  • Mark Ojeda
    Executive Vice President - Cervical and Biologics
  • Scott Lish
    Senior Vice President - Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.